Clinical translation of nuclear export inhibitors in cancer

Seminars in Cancer Biology

Volumn 27, Issue , 2014, Pages 74-86

  Senapedis, William T ^a   Baloglu, Erkan ^a   Landesman, Yosef ^a  

^a Karyopharm Therapeutics   (United States)

Author keywords

Cancer; Exportin 1 (XPO1); Selective Inhibitors of Nuclear Export (SINE); Tumor suppressor proteins (TSP)

Indexed keywords

ANTINEOPLASTIC AGENT; CBS 9106; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXPORTIN 1; IBRUTINIB; KPT 127; KPT 185; KPT 214; KPT 251; KPT 276; LEPTOMYCIN B; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SELECTIVE INHIBITOR OF NUCLEAR EXPORT; SELINEXOR; SORAFENIB; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VERDINEXOR; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; FATIGUE; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LOSS OF APPETITE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUCLEOCYTOPLASMIC TRANSPORT; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STEM CELL TRANSPLANTATION; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; UTERINE CERVIX CANCER; VOMITING; ACTIVE TRANSPORT; ANIMAL; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; TRANSLATIONAL RESEARCH;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84904459489     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.04.005     Document Type: Review

References (182)

1. Ohno M., Fornerod M., Mattaj I.W. Nucleocytoplasmic transport: the last 200 nanometers. Cell 1998, 92:327-336.
2. Cyert M.S. Regulation of nuclear localization during signaling. J Biol Chem 2001, 276:20805-20808.
3. Bednenko J., Cingolani G., Gerace L. Nucleocytoplasmic transport: navigating the channel. Traffic 2003, 4:127-135.
4. Poon I.K., Jans D.A. Regulation of nuclear transport: central role in development and transformation?. Traffic 2005, 6:173-186.
5. Fornerod M., Ohno M., Yoshida M., Mattaj I.W. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997, 90:1051-1060.
6. Kudo N., Matsumori N., Taoka H., Fujiwara D., Schreiner E.P., Wolff B., et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A 1999, 96:9112-9117.
7. Chook Y.M., Suel K.E. Nuclear import by karyopherin-betas: recognition and inhibition. Biochim Biophys Acta 2011, 1813:1593-1606.
8. Kau T.R., Way J.C., Silver P.A. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004, 4:106-117.
9. Mosammaparast N., Pemberton L.F. Karyopherins: from nuclear-transport mediators to nuclear-function regulators. Trends Cell Biol 2004, 14:547-556.
10. Jamali T., Jamali Y., Mehrbod M., Mofrad M.R. Nuclear pore complex: biochemistry and biophysics of nucleocytoplasmic transport in health and disease. Int Rev Cell Mol Biol 2011, 287:233-286.
11. Zheng C., Lin F., Wang S., Xing J. A novel virus-encoded nucleocytoplasmic shuttling protein: the UL3 protein of herpes simplex virus type 1. J Virol Methods 2011, 177:206-210.
12. Zhang F., Fan Y.C., Mu N.N., Zhao J., Sun F.K., Zhao Z.H., et al. Exportin 4 gene expression and DNA promoter methylation status in chronic hepatitis B virus infection. J Viral Hepat 2014, 21:241-250.
13. Daelemans D., Afonina E., Nilsson J., Werner G., Kjems J., De Clercq E., et al. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A 2002, 99:14440-14445.
14. Predicala R., Zhou Y. The role of Ran-binding protein 3 during influenza A virus replication. J Gen Virol 2013, 94:977-984.
15. Turner J.G., Dawson J., Sullivan D.M. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012, 83:1021-1032.
16. Nguyen K.T., Holloway M.P., Altura R.A. The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 2012, 3:137-151.
17. Desmond C.R., Maiuri T., Truant R. A multifunctional, multi-pathway intracellular localization signal in Huntingtin. Commun Integr Biol 2013, 6:e23318.
18. Jang B.C., Sung S.H., Park J.G., Park J.W., Suh M.H., Choi I.H., et al. Leptomycin B, a metabolite of Streptomyces, inhibits the expression of inducible nitric oxide synthase in BV2 microglial cells. Int J Oncol 2006, 29:1509-1515.
19. Jang B.C., Munoz-Najar U., Paik J.H., Claffey K., Yoshida M., Hla T., et al. Leptomycin B, an inhibitor of the nuclear export receptor CRM1, inhibits COX-2 expression. J Biol Chem 2003, 278:2773-2776.
20. Mastroeni D., Chouliaras L., Grover A., Liang W.S., Hauns K., Rogers J., et al. Reduced RAN expression and disrupted transport between cytoplasm and nucleus; a key event in Alzheimer's disease pathophysiology. PLoS One 2013, 8:e53349.
21. Adams J., Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004, 22:304-311.
22. Herndon T.M., Deisseroth A., Kaminskas E., Kane R.C., Koti K.M., Rothmann M.D., et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013, 19:4559-4563.
23. Kalid O., Toledo Warshaviak D., Shechter S., Sherman W., Shacham S. Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors. J Comput Aided Mol Des 2012, 26:1217-1228.
24. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995, 80:179-185.
25. Parsons J.T., Martin K.H., Slack J.K., Taylor J.M., Weed S.A. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 2000, 19:5606-5613.
26. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
27. Cook A., Bono F., Jinek M., Conti E. Structural biology of nucleocytoplasmic transport. Annu Rev Biochem 2007, 76:647-671.
28. Fukuda M., Asano S., Nakamura T., Adachi M., Yoshida M., Yanagida M., et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997, 390:308-311.
29. Harrison B.C., Roberts C.R., Hood D.B., Sweeney M., Gould J.M., Bush E.W., et al. The CRM1 nuclear export receptor controls pathological cardiac gene expression. Mol Cell Biol 2004, 24:10636-10649.
30. Hutten S., Kehlenbach R.H. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol 2007, 17:193-201.
31. Ossareh-Nazari B., Bachelerie F., Dargemont C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science 1997, 278:141-144.
32. Stade K., Ford C.S., Guthrie C., Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 1997, 90:1041-1050.
33. Xu D., Grishin N.V., Chook Y.M. NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell 2012, 23:3673-3676.
34. Xu D., Farmer A., Collett G., Grishin N.V., Chook Y.M. Sequence and structural analyses of nuclear export signals in the NESdb database. Mol Biol Cell 2012, 23:3677-3693.
35. Fu S.C., Huang H.C., Horton P., Juan H.F. ValidNESs: a database of validated leucine-rich nuclear export signals. Nucleic Acids Res 2013, 41:D338-D343.
36. Wolff B., Sanglier J.J., Wang Y. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol 1997, 4:139-147.
37. Kudo N., Khochbin S., Nishi K., Kitano K., Yanagida M., Yoshida M., et al. Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins. J Biol Chem 1997, 272:29742-29751.
38. Dong X., Biswas A., Chook Y.M. Structural basis for assembly and disassembly of the CRM1 nuclear export complex. Nat Struct Mol Biol 2009, 16:558-560.
39. Dong X., Biswas A., Suel K.E., Jackson L.K., Martinez R., Gu H., et al. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 2009, 458:1136-1141.
40. Schwab T.S., Madison B.B., Grauman A.R., Feldman E.L. Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells. Apoptosis 2005, 10:831-840.
41. Wang H., Holloway M.P., Ma L., Cooper Z.A., Riolo M., Samkari A., et al. Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem 2010, 285:36129-36137.
42. Brownawell A.M., Kops G.J., Macara I.G., Burgering B.M. Inhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX. Mol Cell Biol 2001, 21:3534-3546.
43. Vogt P.K., Jiang H., Aoki M. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 2005, 4:908-913.
44. Monovich L., Koch K.A., Burgis R., Osimboni E., Mann T., Wall D., et al. Suppression of HDAC nuclear export and cardiomyocyte hypertrophy by novel irreversible inhibitors of CRM1. Biochim Biophys Acta 2009, 1789:422-431.
45. Noske A., Weichert W., Niesporek S., Roske A., Buckendahl A.C., Koch I., et al. Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 2008, 112:1733-1743.
46. Huang W.Y., Yue L., Qiu W.S., Wang L.W., Zhou X.H., Sun Y.J. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 2009, 32:E315.
47. van der Watt P.J., Maske C.P., Hendricks D.T., Parker M.I., Denny L., Govender D., et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 2009, 124:1829-1840.
48. Shen A., Wang Y., Zhao Y., Zou L., Sun L., Cheng C. Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 2009, 65:153-159. discussion 159-160.
49. Yao Y., Dong Y., Lin F., Zhao H., Shen Z., Chen P., et al. The expression of CRM1 is associated with prognosis in human osteosarcoma. Oncol Rep 2009, 21:229-235.
50. Inoue H., Kauffman M., Shacham S., Landesman Y., Yang J., Evans C.P., et al. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol 2013, 189:2317-2326.
51. Kojima K., Kornblau S.M., Ruvolo V., Dilip A., Duvvuri S., Davis R.E., et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 2013, 121:4166-4174.
52. Puente X.S., Pinyol M., Quesada V., Conde L., Ordonez G.R., Villamor N., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
53. Zhang K., Wang M., Tamayo A.T., Shacham S., Kauffman M., Lee J., et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 2013, 41. 67-78.e64.
54. Lapalombella R., Sun Q., Williams K., Tangeman L., Jha S., Zhong Y., et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012, 120:4621-4634.
55. Schmidt J., Braggio E., Kortuem K.M., Egan J.B., Zhu Y.X., Xin C.S., et al. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia 2013, 27:2357-2365.
56. Pathria G., Wagner C., Wagner S.N. Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways. J Invest Dermatol 2012, 132:2780-2790.
57. Walker C.J., Oaks J.J., Santhanam R., Neviani P., Harb J.G., Ferenchak G., et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 2013, 122:3034-3044.
58. Kanai M., Hanashiro K., Kim S.H., Hanai S., Boulares A.H., Miwa M., et al. Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol 2007, 9:1175-1183.
59. Cai X., Liu X. Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage. Proc Natl Acad Sci U S A 2008, 105:16958-16963.
60. Gaubatz S., Lees J.A., Lindeman G.J., Livingston D.M. E2F4 is exported from the nucleus in a CRM1-dependent manner. Mol Cell Biol 2001, 21:1384-1392.
61. Kau T.R., Schroeder F., Ramaswamy S., Wojciechowski C.L., Zhao J.J., Roberts T.M., et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003, 4:463-476.
62. Huang T.T., Kudo N., Yoshida M., Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci U S A 2000, 97:1014-1019.
63. Mao L., Yang Y. Targeting the nuclear transport machinery by rational drug design. Curr Pharm Des 2013, 19:2318-2325.
64. Hamamoto T., Seto H., Beppu T. Leptomycins A and B, new antifungal antibiotics. II. Structure elucidation. J Antibiot (Tokyo) 1983, 36:646-650.
65. Yoshida M., Horinouchi S. Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export. Ann N Y Acad Sci 1999, 886:23-36.
66. Sun Q., Carrasco Y.P., Hu Y., Guo X., Mirzaei H., Macmillan J., et al. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A 2013, 110:1303-1308.
67. Hamamoto T., Gunji S., Tsuji H., Beppu T. Leptomycins A and B, new antifungal antibiotics. I. Taxonomy of the producing strain and their fermentation, purification and characterization. J Antibiot (Tokyo) 1983, 36:639-645.
68. Yoshida M., Nishikawa M., Nishi K., Abe K., Horinouchi S., Beppu T., et al. Effects of leptomycin B on the cell cycle of fibroblasts and fission yeast cells. Exp Cell Res 1990, 187:150-156.
69. Roberts B.J., Hamelehle K.L., Sebolt J.S., Leopold W.R. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother Pharmacol 1986, 16:95-101.
70. Newlands E.S., Rustin G.J., Brampton M.H. Phase I trial of elactocin. Br J Cancer 1996, 74:648-649.
71. Mutka S.C., Yang W.Q., Dong S.D., Ward S.L., Craig D.A., Timmermans P.B., et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 2009, 69:510-517.
72. Meissner T., Krause E., Vinkemeier U. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms. FEBS Lett 2004, 576:27-30.
73. Van Neck T., Pannecouque C., Vanstreels E., Stevens M., Dehaen W., Daelemans D. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem 2008, 16:9487-9497.
74. Koster M., Lykke-Andersen S., Elnakady Y.A., Gerth K., Washausen P., Hofle G., et al. Ratjadones inhibit nuclear export by blocking CRM1/exportin 1. Exp Cell Res 2003, 286:321-331.
75. Murakami N., Ye Y., Kawanishi M., Aoki S., Kudo N., Yoshida M., et al. New Rev-transport inhibitor with anti-HIV activity from Valerianae Radix. Bioorg Med Chem Lett 2002, 12:2807-2810.
76. Tamura S., Shiomi A., Kaneko M., Ye Y., Yoshida M., Yoshikawa M., et al. New Rev-export inhibitor from Alpinia galanga and structure-activity relationship. Bioorg Med Chem Lett 2009, 19:2555-2557.
77. Sakakibara K., Saito N., Sato T., Suzuki A., Hasegawa Y., Friedman J.M., et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011, 118:3922-3931.
78. Etchin J., Sun Q., Kentsis A., Farmer A., Zhang Z.C., Sanda T., et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 2013, 27:66-74.
79. Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62:220-241.
80. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835-3849.
81. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005, 352:804-815.
82. Longo P.G., Laurenti L., Gobessi S., Sica S., Leone G., Efremov D.G., et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008, 111:846-855.
83. Perrotti D., Jamieson C., Goldman J., Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010, 120:2254-2264.
84. Cortes J., Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood 2012, 120:1390-1397.
85. Hochhaus A., O'Brien S.G., Guilhot F., Druker B.J., Branford S., Foroni L., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
86. Milojkovic D., Apperley J.F., Gerrard G., Ibrahim A.R., Szydlo R., Bua M., et al. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood 2012, 119:1838-1843.
87. Karvela M., Helgason G.V., Holyoake T.L. Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Expert Rev Anticancer Ther 2012, 12:381-392.
88. Lee H.J., Thompson J.E., Wang E.S., Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011, 117:1583-1594.
89. Cortes J.E., Kantarjian H., Shah N.P., Bixby D., Mauro M.J., Flinn I., et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012, 367:2075-2088.
90. Eiring A.M., Neviani P., Santhanam R., Oaks J.J., Chang J.S., Notari M., et al. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood 2008, 111:816-828.
91. Perrotti D., Harb J.G. BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention. Leuk Lymphoma 2011, 52(Suppl. 1):30-44.
92. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371:1030-1043.
93. Pui C.H., Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354:166-178.
94. Estey E., Dohner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
95. Mrozek K., Marcucci G., Paschka P., Whitman S.P., Bloomfield C.D. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 2007, 109:431-448.
96. Falini B., Nicoletti I., Martelli M.F., Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007, 109:874-885.
97. Grisendi S., Mecucci C., Falini B., Pandolfi P.P. Nucleophosmin and cancer. Nat Rev Cancer 2006, 6:493-505.
98. Li Z., Hann S.R. The Myc-nucleophosmin-ARF network: a complex web unveiled. Cell Cycle 2009, 8:2703-2707.
99. Meani N., Alcalay M. Role of nucleophosmin in acute myeloid leukemia. Expert Rev Anticancer Ther 2009, 9:1283-1294.
100. Falini B., Mecucci C., Tiacci E., Alcalay M., Rosati R., Pasqualucci L., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
101. Falini B., Sportoletti P., Martelli M.P. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol 2009, 21:573-581.
102. Cheng K., Sportoletti P., Ito K., Clohessy J.G., Teruya-Feldstein J., Kutok J.L., et al. The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood 2010, 115:3341-3345.
103. Falini B., Bolli N., Shan J., Martelli M.P., Liso A., Pucciarini A., et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006, 107:4514-4523.
104. Aloisi A., Di Gregorio S., Stagno F., Guglielmo P., Mannino F., Sormani M.P., et al. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood 2006, 107:1591-1598.
105. Vigneri P., Wang J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001, 7:228-234.
106. Etchin J., Sanda T., Mansour M.R., Kentsis A., Montero J., Le B.T., et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 2013, 161:117-127.
107. Ranganathan P., Yu X., Na C., Santhanam R., Shacham S., Kauffman M., et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012, 120:1765-1773.
108. Del Gaizo Moore V., Letai A. BH3 profiling-measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett 2013, 332:202-205.
109. Furman R.R., Asgary Z., Mascarenhas J.O., Liou H.C., Schattner E.J. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000, 164:2200-2206.
110. Stilgenbauer S., Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010, 2010:481-488.
111. Rayet B., Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999, 18:6938-6947.
112. Dolcet X., Llobet D., Pallares J., Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005, 446:475-482.
113. Turner J.G., Sullivan D.M. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 2008, 15:2648-2655.
114. Nishio M., Endo T., Tsukada N., Ohata J., Kitada S., Reed J.C., et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005, 106:1012-1020.
115. Johnson A.J., Lucas D.M., Muthusamy N., Smith L.L., Edwards R.B., De Lay M.D., et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006, 108:1334-1338.
116. Jemal A. Global burden of cancer: opportunities for prevention. Lancet 2012, 380:1797-1799.
117. Lardelli P., Bookman M.A., Sundeen J., Longo D.L., Jaffe E.S. Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 1990, 14:752-763.
118. Levine P.H., Hoover R. The emerging epidemic of non-Hodgkin's lymphoma: current knowledge regarding etiological factors. Cancer Epidemiol Biomarkers Prev 1992, 1:515-517.
119. Herrmann A., Hoster E., Zwingers T., Brittinger G., Engelhard M., Meusers P., et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009, 27:511-518.
120. Martin P., Chadburn A., Christos P., Furman R., Ruan J., Joyce M.A., et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008, 19:1327-1330.
121. Bodrug S.E., Warner B.J., Bath M.L., Lindeman G.J., Harris A.W., Adams J.M., et al. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994, 13:2124-2130.
122. Azmi A.S., Al-Katib A., Aboukameel A., McCauley D., Kauffman M., Shacham S., et al. Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas. Haematologica 2013, 98:1098-1106.
123. Pham L.V., Tamayo A.T., Yoshimura L.C., Lo P., Ford R.J. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003, 171:88-95.
124. Fonseca R., Monge J. Myeloma: classification and risk assessment. Semin Oncol 2013, 40:554-566.
125. Katagiri D., Noiri E., Hinoshita F. Multiple myeloma and kidney disease. Sci World J 2013, 2013:487285.
126. Andrews S.W., Kabrah S., May J.E., Donaldson C., Morse H.R. Multiple myeloma: the bone marrow microenvironment and its relation to treatment. Br J Biomed Sci 2013, 70:110-120.
127. Tai Y.T., Landesman Y., Acharya C., Calle Y., Zhong M.Y., Cea M., et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 2014, 28:155-165.
128. Park J., Choi J.H., Bae E.K., Lee C., Jung W.J., Ahn K.S., et al. Establishment and characterization of bortezomib-resistant U266 cell line: Constitutive activation of NF-kappaB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. BMB Rep 2013.
129. Fuchs O. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc Hematol Disord Drug Targets 2013, 13:16-34.
130. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
131. Turner J.G., Marchion D.C., Dawson J.L., Emmons M.F., Hazlehurst L.A., Washausen P., et al. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res 2009, 69:6899-6905.
132. Turner J.G., Dawson J., Emmons M.F., Cubitt C.L., Kauffman M., Shacham S., et al. CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo. J Cancer 2013, 4:614-625.
133. McMillin D.W., Delmore J., Weisberg E., Negri J.M., Geer D.C., Klippel S., et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010, 16:483-489.
134. Cairns P. Renal cell carcinoma. Cancer Biomark 2010, 9:461-473.
135. Belldegrun A.S., Klatte T., Shuch B., LaRochelle J.C., Miller D.C., Said J.W., et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 2008, 113:2457-2463.
136. Motzer R.J., Bukowski R.M. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006, 24:5601-5608.
137. Inoue H., Hwang S.H., Wecksler A.T., Hammock B.D., Weiss R.H. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther 2011, 12:827-836.
138. Voss M.H., Molina A.M., Motzer R.J. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011, 25:835-852.
139. Keefe S.M., Nathanson K.L., Rathmell W.K. The molecular biology of renal cell carcinoma. Semin Oncol 2013, 40:421-428.
140. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
141. Azmi A.S., Aboukameel A., Bao B., Sarkar F.H., Philip P.A., Kauffman M., et al. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 2013, 144:447-456.
142. Azmi A.S., Ahmad A., Banerjee S., Rangnekar V.M., Mohammad R.M., Sarkar F.H. Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM). Pharm Res 2008, 25:2117-2124.
143. Azmi A.S., Wang Z., Burikhanov R., Rangnekar V.M., Wang G., Chen J., et al. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol Cancer Ther 2008, 7:2884-2893.
144. Gurumurthy S., Goswami A., Vasudevan K.M., Rangnekar V.M. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 2005, 25:1146-1161.
145. Bertolotto C. Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica (Cairo) 2013, 2013:635203.
146. Jerant A.F., Johnson J.T., Sheridan C.D., Caffrey T.J. Early detection and treatment of skin cancer. Am Fam Physician 2000, 62:357-368.
147. Jakob J.A., Bassett R.L., Ng C.S., Curry J.L., Joseph R.W., Alvarado G.C., et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118:4014-4023.
148. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714.
149. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012, 367:107-114.
150. Salas Fragomeni R.A., Chung H.W., Landesman Y., Senapedis W., Saint-Martin J.R., Tsao H., et al. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther 2013, 12:1171-1179.
151. Jenkins M.H., Steinberg S.M., Alexander M.P., Fisher J.L., Ernstoff M.S., et al. Multiple murine BRaf melanoma cell lines with sensitivity to PLX4032. Pigment Cell Melanoma Res 2014, 27:495-501.
152. Hocker T., Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 2007, 28:578-588.
153. Muthusamy V., Hobbs C., Nogueira C., Cordon-Cardo C., McKee P.H., Chin L., et al. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 2006, 45:447-454.
154. Mirmohammadsadegh A., Mota R., Gustrau A., Hassan M., Nambiar S., Marini A., et al. ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol 2007, 127:2207-2215.
155. Cagnol S., Chambard J.C. ERK and cell death: mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence. FEBS J 2010, 277:2-21.
156. Hudis C.A., Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011, 16(Suppl. 1):1-11.
157. Bramati A., Girelli S., Torri V., Farina G., Galfrascoli E., Piva S., et al. Efficacy of biological agents in metastatic triple-negative breast cancer. Cancer Treat Rev 2014, 40:605-613.
158. McCauley D., Landesman Y., Senapedis W., Kashyap T., Saint-Martin J.-R., Plamondon L., et al. Abstract 1055: preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC). J Clin Oncol 2012, 30. Abstract 1055.
159. Tanaka K., Iwamoto S., Gon G., Nohara T., Iwamoto M., Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000, 6:127-134.
160. Chan K.S., Wong C.H., Huang Y.F., Li H.Y. Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis 2010, 1:e57.
161. Knauer S.K., Kramer O.H., Knosel T., Engels K., Rodel F., Kovacs A.F., et al. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 2007, 21:207-216.
162. Diaz N., Minton S., Cox C., Bowman T., Gritsko T., Garcia R., et al. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res 2006, 12:20-28.
163. Gritsko T., Williams A., Turkson J., Kaneko S., Bowman T., Huang M., et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006, 12:11-19.
164. Cheng Y., Holloway M.P., Nguyen K., McCauley D., Landesman Y., Kauffman M.G., et al. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple negative breast cancer. Mol Cancer Ther 2014, 13:675-686.
165. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
166. Ramalingam S.S., Owonikoko T.K., Khuri F.R. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 2011, 61:91-112.
167. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
168. Wang S., Han X., Wang J., Yao J., Shi Y. Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts. PLoS One 2014, 9:e89848.
169. Gravina G.L., Tortoreto M., Mancini A., Muzi P., Ventura L., D'ascenzo S., et al. Abstract 3440: CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce the incidence of tumor spreading and improve overall survival in preclinical models of prostate cancer. Cancer Res 2013, 73:3440.
170. Gravina G.L., Ricevuto E., Mancini A., Shechter S., Sandanayaka V., Kauffman M.G., et al. Abstract 1841: Selective inhibitors of nuclear export (SINE) activate multiple tumor suppressor pathways and kill prostate cancer cells across multiple genotypes in vitro and in vivo. Cancer Res 2012, 72:1841.
171. Chen Y., Kalir E., Camacho-Vanegas C., Huang F., Pereira E., Landesman Y., et al. Abstract 2163: Increased overall survival in platinum-resistant ovarian cancer: paradigmatic use of novel SINE (selective inhibitor of nuclear export), which restores p53 nuclear localization and activation. Cancer Res 2013, 73:2163.
172. Miyake T.M., Pradeep S., Zand B., Dalton H.J., Wen Y., Armaitz Pena G.N., et al. Abstract 5541: therapeutic targeting of CRM1 in ovarian cancer. Cancer Res 2013, 73:5541.
173. Fan T.M. Lymphoma updates. Vet Clin North Am Small Anim Pract 2003, 33:455-471.
174. Marconato L. The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects. Vet J 2011, 188:34-38.
175. Marconato L., Gelain M.E., Comazzi S. The dog as a possible animal model for human non-Hodgkin lymphoma: a review. Hematol Oncol 2013, 31:1-9.
176. Marconato L., Stefanello D., Valenti P., Bonfanti U., Comazzi S., Roccabianca P., et al. Predictors of long-term survival in dogs with high-grade multicentric lymphoma. J Am Vet Med Assoc 2011, 238:480-485.
177. Diefenbach C., Advani R. Customized targeted therapy in Hodgkin lymphoma: hype or hope?. Hematol Oncol Clin North Am 2014, 28:105-122.
178. London C.A., Bernabe L.F., Barnard S., Kisseberth W.C., Borgatti A., Henson M., et al. Preclinical Evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. PLoS One 2014, 9:e87585.
179. Savona M., Garzon R., Brown P.d.N., Yee K., Lancet J.E., Gutierrez M., et al. Phase I trial of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with advanced acute myelogenous leukemia (AML). Blood 2013, 122:1440.
180. Kuruvilla J., Gutierrez M., Shah B.D., Gabrail N.Y., de Nully Brown P., Stone R.M., et al. Preliminary evidence of anti tumor activity of selinexor (KPT-330) in a phase I trial of a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with relapsed/refractory non Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Blood 2013, 122:90.
181. Chen C.I., Gutierrez M., de Nully Brown P., Gabrail N., Baz R., Reece D.E., et al. Anti tumor activity of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) XPO1/CRM1 antagonist in patients (pts) with relapsed/refractory multiple myeloma (MM) or Waldenstrom's macroglobulinemia (WM). Blood 2013, 122:1942.
182. Razak A.R.A., Soerensen M.M., Mahipal A., Shacham S., Yau C.Y.F., Lassen U.N., et al. Abstract 2505: First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. J Clin Oncol 2013, 31. Abstract 2505.